BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

  October 19, 2026

   · 

  3 min read
• Press Releases

  Faron to Report Final Melanoma Survival Data from the MATINS Study at ESMO 2026

  October 19, 2026

   · 

  7 min read
• Press Releases

  Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

  October 19, 2026

   · 

  6 min read
• Press Releases

  Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation

  October 19, 2026

   · 

  7 min read
• Press Releases

  AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn’s Disease

  October 19, 2026

   · 

  11 min read
• Press Releases

  Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer

  October 19, 2026

   · 

  5 min read
• Press Releases

  Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - October 19, 2026

  October 19, 2026

   · 

  2 min read
• Press Releases

  Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

  October 19, 2026

   · 

  15 min read
• Press Releases

  Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference Call

  October 19, 2026

   · 

  4 min read
• Press Releases

  First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

  October 19, 2026

   · 

  16 min read